# Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

> **NCT00657813** · PHASE1 · TERMINATED · sponsor: **Institute for Neurodegenerative Disorders** · enrollment: 3 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** MNI-330 as a brain SPECT tracer of Beta-Amyloid

## Key facts

- **NCT ID:** NCT00657813
- **Lead sponsor:** Institute for Neurodegenerative Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2008-09-30
- **Final completion:** 2008-09-30
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Data did not evidence \[123I\]MNI-330 as a useful tool in the detection of AD.
- **Last updated:** 2019-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657813, "Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00657813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*